Prosecution Insights
Last updated: October 04, 2026
Application No. 18/668,678

ALLOSTERIC INHIBITOR OF WEE1 KINASE

Final Rejection §102
Filed
May 20, 2024
Priority
Aug 03, 2018 — provisional 62/714,351 +2 more
Examiner
ANDERSON, REBECCA L
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
H. Lee Moffitt Cancer Center and Research Institute Inc.
OA Round
4 (Final)
73%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
766 granted / 1044 resolved
+13.4% vs TC avg
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
49 currently pending
Career history
1095
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
18.8%
-21.2% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
32.8%
-7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1044 resolved cases

Office Action

§102
DETAILED ACTION Claims 1-4 are currently pending in the instant application. Claim 1 is rejected. Claims 2-4 are withdrawn from consideration as being for non-elected subject matter. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I and the species: PNG media_image1.png 94 312 media_image1.png Greyscale in the reply filed on 25 February 2025 has been previously acknowledged. According to MPEP 803.02, the examiner has previously determined whether the elected species is allowable. Applicants’ elected species appears allowable. As applicant has amended claim 1 to overcome the 35 USC 102(a)(1) rejection as being anticipated by Sarkar et al. Journal of Applied Polymer Science, Vol. 105, 1793-1801 (2007), the examiner has now extended the search and examination according to MPEP 803.02 to the compound PNG media_image2.png 138 262 media_image2.png Greyscale which is not allowable. Claim 1 has been examined to the extent that it is readable on the elected embodiment, the elected species and the above mentioned compound. Response to Amendment and Remarks Applicant's amendment and remarks filed 8 July 2026 have been fully considered and entered into the instant application. Applicant’s amendment to delete the compound PNG media_image3.png 126 260 media_image3.png Greyscale has overcome the 35 USC 102(a)(1) rejection as being anticipated by Sarkar et al. Journal of Applied Polymer Science, Vol. 105, 1793-1801 (2007). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Registry Number 1372048-27-5. Registry Number 1372048-27-5 is PNG media_image4.png 164 500 media_image4.png Greyscale . This compound corresponds to and anticipates the tenth listed compound of claim 1 which is formula PNG media_image2.png 138 262 media_image2.png Greyscale . Therefore, claim 1 is anticipated. Registry number 1372048-27-5 is available as prior art as of 01 May 2012 the date it was indexed into the CAplus database. See MPEP 2128: ELECTRONIC PUBLICATIONS AS PRIOR ART Status as a "Printed Publication" An electronic publication, including an on-line database or Internet publication, is considered to be a “printed publication” within the meaning of 35 U.S.C. 102(a) and (b) provided the publication was accessible to persons concerned with the art to which the document relates. See In re Wyer, 655 F.2d 221, 227, 210 USPQ 790, 795 (CCPA 1981) Since this date represents the date that each compound entered the CAPlus database on STN, this represents the date that each compound was made accessible to the public. The aforementioned compound anticipates the instantly claimed compounds: It is further noted that for the purposes of determining if a reference is a “printed publication” for the purposes of 102(b), MPEP 2128 states the following: PNG media_image5.png 99 480 media_image5.png Greyscale where “prior art disclosures…on an on-line database are considered to be publicly available as of the date the item was publicly posted.” Since each of the database entries above lists the date that each compound was entered into the on-line database, the compounds were made publicly available as of that date in each citation, and the claims are anticipated. Claim(s) 1 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhang et al. Zhang et al. discloses the compound III on page 404: PNG media_image6.png 370 474 media_image6.png Greyscale which corresponds to PNG media_image4.png 164 500 media_image4.png Greyscale . This compound corresponds to and anticipates the tenth listed compound of claim 1 which is formula PNG media_image2.png 138 262 media_image2.png Greyscale . Therefore, claim 1 is anticipated. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA L ANDERSON whose telephone number is (571)272-0696. The examiner can normally be reached Monday-Friday from 6am-2pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA L ANDERSON/Primary Examiner, Art Unit 1626 ____________________ 13 September 2026 Rebecca Anderson Primary Examiner Art Unit 1626, Group 1620 Technology Center 1600
Read full office action

Prosecution Timeline

Show 1 earlier event
Mar 07, 2025
Non-Final Rejection mailed — §102
Jul 07, 2025
Response Filed
Jul 28, 2025
Final Rejection mailed — §102
Dec 29, 2025
Request for Continued Examination
Jan 06, 2026
Response after Non-Final Action
Jan 09, 2026
Non-Final Rejection mailed — §102
Jul 08, 2026
Response Filed
Sep 16, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735385
ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS
2y 10m to grant Granted Sep 15, 2026
Patent 12729196
N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES
3y 2m to grant Granted Sep 08, 2026
Patent 12715864
PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE
3y 9m to grant Granted Aug 25, 2026
Patent 12703706
ANTHELMINTIC COMPOUNDS COMPRISING A THIENOPYRIDINE STRUCTURE
3y 2m to grant Granted Aug 11, 2026
Patent 12692233
ANTHELMINTIC COMPOUNDS COMPRISING A PYRIDINE STRUCTURE
3y 1m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+23.6%)
2y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1044 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month